319 related articles for article (PubMed ID: 17158539)
1. Trimodality treatment and selective organ preservation for bladder cancer.
Rödel C; Weiss C; Sauer R
J Clin Oncol; 2006 Dec; 24(35):5536-44. PubMed ID: 17158539
[TBL] [Abstract][Full Text] [Related]
2. Radiochemotherapy for bladder cancer.
Ott OJ; Rödel C; Weiss C; Wittlinger M; St Krause F; Dunst J; Fietkau R; Sauer R
Clin Oncol (R Coll Radiol); 2009 Sep; 21(7):557-65. PubMed ID: 19564101
[TBL] [Abstract][Full Text] [Related]
3. Current status of radiation therapy and combined-modality treatment for bladder cancer.
Rödel C
Strahlenther Onkol; 2004 Nov; 180(11):701-9. PubMed ID: 15549188
[TBL] [Abstract][Full Text] [Related]
4. Selective organ preservation in muscle-invasive bladder cancer: review of the literature.
Khosravi-Shahi P; Cabezón-Gutiérrez L
Surg Oncol; 2012 Mar; 21(1):e17-22. PubMed ID: 22088598
[TBL] [Abstract][Full Text] [Related]
5. Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
Mak RH; Zietman AL; Heney NM; Kaufman DS; Shipley WU
BJU Int; 2008 Nov; 102(9 Pt B):1345-53. PubMed ID: 19035903
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
[TBL] [Abstract][Full Text] [Related]
7. Overview of bladder cancer trials in the Radiation Therapy Oncology Group.
Shipley WU; Kaufman DS; Tester WJ; Pilepich MV; Sandler HM;
Cancer; 2003 Apr; 97(8 Suppl):2115-9. PubMed ID: 12673704
[TBL] [Abstract][Full Text] [Related]
8. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.
Shipley WU; Kaufman DS; Heney NM; Althausen AF; Zietman AL
J Urol; 1999 Aug; 162(2):445-50; discussion 450-1. PubMed ID: 10411054
[TBL] [Abstract][Full Text] [Related]
9. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
[TBL] [Abstract][Full Text] [Related]
10. Organ preservation for muscle-invasive bladder cancer by transurethral resection.
Leibovici D; Kassouf W; Pisters LL; Pettaway CA; Wu X; Dinney CP; Grossman HB
Urology; 2007 Sep; 70(3):473-6. PubMed ID: 17905099
[TBL] [Abstract][Full Text] [Related]
11. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
12. Bladder preserving strategies for muscle-invasive bladder cancer.
Merseburger AS; Matuschek I; Kuczyk MA
Curr Opin Urol; 2008 Sep; 18(5):513-8. PubMed ID: 18670277
[TBL] [Abstract][Full Text] [Related]
13. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.
Tsai HK; Katz MS; Coen JJ; Zietman AL; Kaufman DS; Shipley WU
Urology; 2006 Dec; 68(6):1188-92. PubMed ID: 17141846
[TBL] [Abstract][Full Text] [Related]
14. Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer.
Akçetin Z; Todorov J; Tüzel E; Engehausen DG; Krause FS; Sauer R; Schrott KM; Rödel C
Anticancer Res; 2005; 25(3A):1623-8. PubMed ID: 16033071
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties.
Choueiri TK; Raghavan D
Nat Clin Pract Oncol; 2008 Aug; 5(8):444-54. PubMed ID: 18577983
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer.
Chung PW; Bristow RG; Milosevic MF; Yi QL; Jewett MA; Warde PR; Catton CN; McLean M; Moore M; Tannock IF; Gospodarowicz MK
Urol Oncol; 2007; 25(4):303-9. PubMed ID: 17628296
[TBL] [Abstract][Full Text] [Related]
17. Selection of treatment for muscle infiltrating transitional cell bladder cancer.
Whitmore WF
Arch Esp Urol; 1990; 43 Suppl 2():219-22. PubMed ID: 2096783
[TBL] [Abstract][Full Text] [Related]
18. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer.
Weiss C; Engehausen DG; Krause FS; Papadopoulos T; Dunst J; Sauer R; Rödel C
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1072-80. PubMed ID: 17467193
[TBL] [Abstract][Full Text] [Related]
19. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
